Cinta Hierro

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i> / <i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study

Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro et al. · Cancer Discovery · 2021 · 239 citations · Full text

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Rastislav Bahleda, Antoîne Italiano, Cinta Hierro et al. · Clinical Cancer Research · 2019 · 237 citations · Full text

KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer

Ken Kato, Manish A. Shah, Peter C. Enzinger et al. · Future Oncology · 2019 · 168 citations · Full text

Esophageal Cancer, Immunology, Gastroenterology +16

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations

Martin H. Voss, Cinta Hierro, Rebecca S. Heist et al. · Clinical Cancer Research · 2019 · 120 citations · Full text

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Marta Ligero, Alonso García-Ruiz, Cristina Viaplana et al. · Radiology · 2021 · 102 citations